Continued/Ongoing Process Verification - How to handle part 3 of the validation life cycle

13-14 June 2017, Berlin, Germany

Course No. 15910

header-image

Speakers

Timur Güvercinci, Merck KGaA, Germany

Gert Moelgaard, Head of ECA´s Validation Group, Denmark

Dr Bettina Knapp, Boehringer Ingelheim, Germany

Dr Thomas Schneppe, Bayer Pharma AG, Germany

Dr Chris Watts, VoPal, USA, Formerly with FDA

Objectives

With the Guidance for Industry “Process Validation: General Principles and Practices”, the FDA requires a new direction. Validation is now a „Life Cycle Process” with 3 stages:

Process Design
Process Qualification
Continued Process Verification

The stage 3 “Continued Process Verification” is a new step in validation. Also legacy process should be (re)validated regarding this life cycle. The start is stage 3 “Continued Process Verification”. The goal of the third validation stage is continual assurance that the process remains in a state of control (the validated state) during commercial manufacture. A system or systems for detecting unplanned departures from the process as designed is essential to accomplish this goal, says the Guidance. Now, also the EU requires Ongoing Process Verification as part of a validation lifecycle.

  • But how to implement Continued/Ongoing Process Verification in the routine production?
  • What is state of the art regarding systems for detecting unplanned departures from the process?
  • How to handle the monitoring at Stage 3 (Continued/Ongoing Process Verification)?
  • What are the differences between Continued Process Verification (FDA) and Continuous Process Verification (ICH Q8) and Ongoing Process Verification (EU)?
  • Are there parallels regarding Medical Devices?
  • What statistic parameters could help
These questions are discussed, and the possibilities for implementation are covered.

Background

Since 1987 the FDA Guideline on Process Validation has been the basis for qualification and validation. Within the new FDA programme “Pharmaceutical cGMPs for the 21st Century” there was an announcement for a revision of the guideline. A new FDA Policy Guide of 2004 gives some hints as to the new validation approach. In January 2011 the new “Guidance for Industry Process Validation: General Principles and Practices” was published as final guidance. That is now FDA’s „current thinking“. EMA´s new Process Validation Guidance also mentions a Life Cycle Approach for Process Validation. And with the citation of ICH Q8, the possibility to do Continuous Process Verification is also mentioned. In the new Annex 15 draft revision document also a Continued Process Verification, Ongoing Process Verification called, is mentioned. In the new Annex 15 revision document, valid from 1 October 2015, also a Continued Process Verification, called Ongoing Process Verification, is mentioned.

Target Group

The addressees of the event are qualified staff charged with or responsible for validation activities, especially regarding stage 3 (Continued/Ongoing Process Verification) of the process validation life cycle. We mean commissioners for validation, heads of quality assurance, department heads, etc. It also addresses members of validation teams (e.g. chemists, pharmacists, microbiologists) as well as staff who is involved in process monitoring activities and consultants.

Programme

Overview: The new process validation guides from FDA and EMA and the new industry guides from ISPE, PDA and ECA: content and principles

  • How the concept of Process Validation is about to change
  • Ongoing changes in the Quality Management philosophy
  • Comparision of Annex 15 revision with FDA Process Validation Guidance
  • Real-life examples
Parallels between Medical Device and Drug Process Validation
  • Leveraging experience
  • Quality System similarities
  • Standard Approaches – foundation for implementation
Case Study: From Control Strategy to Trending
  • Introduction in Biopharmaceutical Processes
  • Process development and definition of parameters
  • Parameters and control
  • Control Strategy and CPV/Trending
  • Case Study
  • Trending Report
Case Study: Large Molecules: Process Validation and Statistical Trending in Biopharmaceutical Manufacturing
  • Process Performance Validation Approach
  • Trending program and related procedures
  • Link to APR/PQR
  • Case Study
Recent trends in FDA inspections, observations and warning letters
  • Examples of expectations and enforcement
  • Regulatory enforcement trends related to observations and Warning Letters
Case Study: How to implement CPV of a legacy process
  • Challenges
  • Experiences
  • Lessons learnt
The bridge between the traditional and a new life cycle validation approach - the way to continuous process verification
  • Hybrid validation approach as a interim solution
  • Technology upgrade
  • Outlook
The future role of PAT, industrial IT and automation in continued process verification: Implementing a control strategy
  • Control strategy and implications for automation solutions
  • Bridging islands of information systems in manufacturing
  • From data to information to knowledge: getting gold out of data
  • Continued process verification: monitoring challenges
  • Window to the Quality: The future role of automation and IT systems in manufacturing?

Workshop Continued Process Verification – Process Data Evaluation and Conclusions
The delegates analyse in small groups process data regarding the validity of a legacy process.

stop

This course is part of the GMP Certification Programme "ECA Certified Validation Manager" Learn more

This training/webinar cannot be booked. Send us your inquiry by using the following contact form.

To find alternative dates for this training/webinar or similar events please see the complete list of all events.

For many training courses and webinars, there are also recordings you can order and watch any time. Just take a look at the complete list of all recordings.

* also payable by credit card
American Express Visa Mastercard

icon
Further dates on-site
Further dates on-site
Not available
icon
Further dates online
Further dates online
Not available
icon
Recording
Not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0
E-Mail: info@gmp-compliance.org

Woman with headset

Go back

Testimonials about our courses and conferences

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023

 

“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024

 

“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024

 

 

“Well prepared presentations and good presenters. I also like the way of asking questions.”

Alexandra Weidler, Hookipa Biotech GmbH, Austria
Live Online Training – QP Education Course Module A, November 2023